Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 inhibitor use, according to data presented at the American College of ...

Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.

Semaglutide 2.4 mg reduced total cardiovascular events by 22% in people with established cardiovascular disease (CVD) and overweight or obesity without diabetes. 1 Obesity directly leads to ...

The initial findings demonstrated a significant reduction in major adverse cardiovascular events, leading Health Canada to grant the first-ever indication for semaglutide 2.4 mg in individuals ...